An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) (clinicaltrials.gov) - Oct 15, 2026 - P3 | N=5700 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Recruiting ➔ Active, not recruiting
Enrollment closed • Cardiovascular
|